Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals.
about
HIV-1 drug resistance and resistance testing.A Robust PCR Protocol for HIV Drug Resistance Testing on Low-Level Viremia Samples.Temporal Patterns and Drug Resistance in CSF Viral Escape Among ART-Experienced HIV-1 Infected AdultsPhylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia.Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients.Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection.Relevance of undetectably rare resistant malaria parasites in treatment failure: experimental evidence from Plasmodium chabaudi.HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective.Predicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithmInitiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes.HIV drug resistance testing by high-multiplex "wide" sequencing on the MiSeq instrument.Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings.HIV drug resistance testing among patients failing second line antiretroviral therapy. Comparison of in-house and commercial sequencing.Genotypic susceptibility score (GSS) and CD4+ T cell recovery in HIV-1 patients with suppressed viral load.An assessment of the relationship between the World Health Organization HIV drug resistance early warning indicators and HIV drug resistance acquisition.Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: a MASTER cohort study.Determinants of virological failure and antiretroviral drug resistance in Mozambique.Implementation of Next-Generation Sequencing for Hepatitis B Virus Resistance Testing and Genotyping in a Clinical Microbiology Laboratory.Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study.HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.Feasibility and reproducibility of HIV-1 genotype resistance test in very-low-level viremia.Editorial Commentary: Extending HIV drug resistance testing to low levels of plasma viremia.Human Immunodeficiency Virus Resistance Testing Technologies and Their Applicability in Resource-Limited Settings of Africa.Alternative Sample Types for HIV-1 Antiretroviral Drug Resistance Testing.Extensive host immune adaptation in a concentrated North American HIV epidemicSelective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir
P2860
Q30245693-F02A93D8-18B8-4FEF-B81C-B17ACDC89A5FQ33572108-82BB9762-93D5-4D4B-B3BD-AE993E067EE6Q33750994-388962C9-CEFE-43B5-81A1-EDF08C61C10DQ34289476-0915C800-7B1B-4AB9-B8E1-417F3045062FQ34420782-9D9CDE75-892D-4F55-B160-B3E91E50986BQ35577906-44CD108D-B598-4670-A026-E48744F58DA8Q35692528-29EA3A95-AFB3-4513-9DCF-78C66AD17325Q35698144-366FD81E-5DFF-49D8-8DCF-42672762CD4EQ36050916-2BC7B8D8-D960-4F2E-B4DD-25B50CC5C5DDQ36070585-9F0F5B7E-8F7A-4F7A-9D3F-204587ADBF82Q36158371-04313F52-6EA3-4ECB-8E19-D2A2E3591C5EQ37157278-46F90435-8D58-4795-BF0B-6035B620B386Q38375479-62BEBA1F-85D0-43CB-AF74-AC46C07AED9AQ39080507-2624431A-B2F6-4A1B-BCF5-A2EF1BEF6EE7Q39321642-68B0A799-6461-49AB-BCC9-52EDBF959452Q39375437-485EBBBF-ADA2-4E4B-9A54-BD4C4B5F7745Q39414398-15E388D1-801E-4553-9466-9E39ADF0759AQ40355667-6B02EB79-940E-434E-B84A-9194BC35618FQ40693320-2246EB74-674D-406E-9EDB-A828B7541902Q41465991-3CFD1F30-1ED5-4DB9-B167-5CEEA97A7487Q43045837-BAC977C4-4E09-4B96-8B7F-C691F108D57AQ44864490-02AFB170-7460-4C40-A7BF-DB26969BE7F8Q47113253-74EC0688-BAFC-46F3-868A-FB2179875FA1Q47613741-0F8EF373-2576-45FB-B4D7-EAEE290104BFQ58767928-44280DFE-85DC-409F-B259-1CAE2C216221Q58770498-CEA08A62-5FC5-4F23-A6F2-6CE3ABAD1988
P2860
Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Performance of HIV-1 drug resi ...... n treatment-naive individuals.
@en
Performance of HIV-1 drug resi ...... n treatment-naive individuals.
@nl
type
label
Performance of HIV-1 drug resi ...... n treatment-naive individuals.
@en
Performance of HIV-1 drug resi ...... n treatment-naive individuals.
@nl
prefLabel
Performance of HIV-1 drug resi ...... n treatment-naive individuals.
@en
Performance of HIV-1 drug resi ...... n treatment-naive individuals.
@nl
P2093
P2860
P356
P1476
Performance of HIV-1 drug resi ...... n treatment-naive individuals.
@en
P2093
A Gonzalez-Serna
J S G Montaner
P R Harrigan
P2860
P304
P356
10.1093/CID/CIU019
P407
P50
P577
2014-01-14T00:00:00Z